中島 振一郎

Medicine & Life Sciences

1. Schizophrenia 100%
2. Antipsychotic Agents 59%
3. Systematic Reviews 41%
4. Dopamine D2 Receptors 30%
5. naxagolide 28%
6. Alzheimer Disease 26%
7. Meta-Analysis 26%
8. Transcranial Magnetic Stimulation 24%
9. Cognitive Dysfunction 24%
10. Proton Magnetic Resonance Spectroscopy 23%
11. Positron-Emission Tomography 21%
12. Depression 21%
13. Dopamine 21%
14. Glutamic Acid 20%
15. Cognition 19%
16. Clozapine 19%
17. Corpus Striatum 17%
18. Raclopride 17%
19. Psychotic Disorders 16%
20. Major Depressive Disorder 16%
21. Ventral Striatum 16%
22. Olanzapine 15%
23. Therapeutics 14%
24. Clinical Trials 14%
25. Brain 13%
26. Neuroimaging 13%
27. Amyloid 13%
28. Risperidone 12%
29. Gyrus Cinguli 12%
30. Prefrontal Cortex 11%
31. Antidepressive Agents 10%
32. Neurophysiology 10%
33. Dopamine D3 Receptors 9%
34. Mental Disorders 8%
35. Biomarkers 7%
36. AMPA Receptors 7%
37. Hippocampus 7%
38. Glutamine 7%
39. Magnetic Resonance Spectroscopy 7%
40. Equipment and Supplies 6%
41. Electroencephalography 6%
42. Dementia 6%
43. Mirtazapine 6%
44. Treatment-Resistant Depressive Disorder 6%
45. Cross-Sectional Studies 6%
46. Regression Analysis 6%
47. Polypharmacy 6%
48. Demography 5%
49. Magnetic Resonance Imaging 5%
50. Datasets 5%